Carvedilol Day6

PreclinicalSmall molecule

IInstitute of Liver and Biliary Sciences, India

Carvedilol Day6 is one of 60 small molecule programs targeting Portal Hypertension. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Portal HypertensionActive, not recruiting

CirrhosisActive, not recruiting

Portal HypertensionPreclinical

Active, not recruiting

CirrhosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

75 competitors in Cirrhosis

#DrugCompanyPhaseTrials

Emtriva

Gilead

Approved

1 2

Cymbalta

Jazz Pharmaceuticals

Approved

1 3

Aldactone

Pfizer

Approved

1 4

Zocor

OOrganon and Co

Approved

5 5

Chronulac

SSolvay Pharmaceuticals

Approved

4 6

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

3 7

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 8

Bumex

VValidus Pharmaceuticals

Phase 3

1 9

Crestor

AstraZeneca

Phase 2

2 10

Savaysa

Daiichi Sankyo

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Portal Hypertension1 trial

To Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Esophageal Varices.

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02465645·220 enrolled

Cirrhosis1 trial

To Study the Hemodynamic Response of Early Addition of Carvedilol to Terlipressin in Acute Variceal Bleed in Child's B and C Cirrhosis

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT05699824·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Carvedilol Day6. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carvedilol Day6 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carvedilol Day6. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Liver and Biliary Sciences, India company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInstitute of Liver and Biliary Sciences, India

Carvedilol Day6

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Portal Hypertension1 trial

Cirrhosis1 trial

References

Drug Info

Quick Facts

Related News